mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy

Gold, Samuel; VanderWeele, David J.; Harmon, Stephanie; Bloom, Jonathan; Karzai, Fatima; Hale, Graham; Marhamati, Shawn; Rayn, Kareem; Mehralivand, Sherif; Merino, María J.; Gulley, James L.; Bilušić, Marijo; Madan, Ravi A.; Choyke, Peter L.; Türkbey, Barış; Dahut, William L.; Pinto, Peter A.

doi:10.1016/j.urolonc.2019.01.012

Cited by 6 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, hyperintensity within prostate in DWI can be regarded as a mark of PCa tissues existence and it was reported useful in many situations include primary diagnosis and assessment after RP 25,26 . Some studied reported DWI signal may provide the information of lesion changes treated by ADT 27,28 . In our study, hyperintensity in DWI/hypointensity in ADC within prostate was related to the bPFS which directly reflected presence of residual tumor after NT.…”

Section: Discussionmentioning

confidence: 50%

“…25,26 Some studied reported DWI signal may provide the information of lesion changes treated by ADT. 27,28 As for other parameters, PI-RADS score among three groups were almost at 5 and it is hard to find out the significance of prognosis. PSA level showed no significance in multivariable Cox regression analysis for that three different groups of treatment had a great disparity before surgery about PSA.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy

Wang

Fan

et al. 2021

The Prostate

View full text Add to dashboard Cite

Objective: To establish the prognostic nomogram for locally advanced prostate cancer (LAPC) patients treated by radical prostatectomy (RP) based on clinical and multiparametric-MRI (mp-MRI) metrics.Methods: One hundred and twenty-one patients diagnosed with LAPC were included in this study. They were all examined by mp-MRI within one week before surgery and treated by RP (36 with RP alone, 48 with neoadjuvant hormonal therapy (NHT) and 37 with neoadjuvant chemohormonal therapy (NCHT)). The biochemical progression-free survival (bPFS) was analyzed by Kaplan-Meier method. Univariate and multivariate analysis were used to determine prognostic factors that were related with bPFS.The prognostic nomogram was established by factors that were significant in multivariate analyses. Results:The median bPFS had significant difference in the subgroup of treatment (RP

show abstract

Section: Discussionmentioning

confidence: 50%

Section: Discussionmentioning

confidence: 98%

The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy

Wang

Fan

et al. 2021

The Prostate

View full text Add to dashboard Cite

show abstract

“…After the screening, a full-text review of 30 articles was performed. According to our inclusion criteria, we finally identified 20 studies eligible for systematic review [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]. Of the twenty studies, we identified eight phase II RCTs comparing the efficacy and/or safety of ARSI-based combination therapy versus other combinations or ADT/ARSI alone (Table 1) [13][14][15][16][17][18][19][20].…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…The radiographic evaluation of treatment efficacy during neoadjuvant therapy is necessary to assess the success/failure of this treatment strategy. In 2019, Gold et al conducted a phase II study to assess the diagnostic performance of multiparametric MRI (mpMRI) to evaluate/estimate disease severity and extent in 20 patients treated with neoadjuvant ENZ + ADT [25]. The authors showed a satisfactory positive predictive value of extraprostatic extension (71%), seminal vesicle invasion (80%), and organ-confined disease (80%) [25].…”

Section: Radiographic Assessment Of Treatment Efficacy In Patients Tr...mentioning

confidence: 99%

“…In 2019, Gold et al conducted a phase II study to assess the diagnostic performance of multiparametric MRI (mpMRI) to evaluate/estimate disease severity and extent in 20 patients treated with neoadjuvant ENZ + ADT [25]. The authors showed a satisfactory positive predictive value of extraprostatic extension (71%), seminal vesicle invasion (80%), and organ-confined disease (80%) [25]. However, a phase II RCT by McKay et al in 2021 reported a low concordance and correlation between mpMRI findings after neoadjuvant ARSI-based combination therapy and pathological residual tumor volume and pCR [17].…”

Section: Radiographic Assessment Of Treatment Efficacy In Patients Tr...mentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

Yanagisawa

Rajwa

Quhal

et al. 2023

JPM

View full text Add to dashboard Cite

(1) Background: Several phase II studies, including randomized controlled trials (RCTs), assessed the efficacy of adding androgen receptor signaling inhibitors (ARSIs) to androgen deprivation therapy (ADT) as a neoadjuvant treatment in patients treated with radical prostatectomy (RP) for prostate cancer (PCa). Summarizing the early results of these studies could help in designing phase III trials and patient counseling. (2) Methods: We queried three databases in January 2023 for studies that included PCa patients treated with neoadjuvant ARSI-based combination therapy before RP. The outcomes of interest were oncologic outcomes and pathologic responses, such as pathologic complete response (pCR) and minimal residual disease (MRD). (3) Results: Overall, twenty studies (eight RCTs) were included in this systematic review. Compared to ADT or ARSI alone, ARSI + ADT was associated with higher pCR and MRD rates; this effect was less evident when adding a second ARSI or chemotherapy. Nevertheless, ARSI + ADT resulted in relatively low pCR rates (0–13%) with a high proportion of ypT3 (48–90%) in the resected specimen. PTEN loss, ERG positive, or intraductal carcinoma seem to be associated with worse pathologic response. One study that adjusted for the effects of possible confounders reported that neoadjuvant ARSI + ADT improved time to biochemical recurrence and metastasis-free survival compared to RP alone. (4) Conclusions: Neoadjuvant ARSI + ADT combination therapy results in improved pathologic response compared to either alone or none in patients with non-metastatic advanced PCa. Ongoing phase III RCTs with long-term oncologic outcomes, as well as biomarker-guided studies, will clarify the indication, oncologic benefits, and adverse events of ARSI + ADT in patients with clinically and biologically aggressive PCa.

show abstract

The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

Wang,

Fu,

Chen

et al. 2024

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy

Cited by 6 publications

References 18 publications

The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy

The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review

The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

Contact Info

Product

Resources

About